AI could spot brittle bones from routine chest X-Rays

NCT ID NCT07421713

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an artificial intelligence software called Osteo Signal that analyzes chest X-rays to detect signs of osteoporosis or osteopenia in adults aged 50 and older. Researchers will compare the AI's accuracy against the standard DXA bone density scan using data from 595 people who already had both exams. If it works, this could make osteoporosis screening faster and more accessible without extra tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Osteo Signal (AI software)
What this could lead to
If successful, this could provide a quick, low-cost way to screen for osteoporosis using routine chest X-rays, without extra radiation or visits.
What could go wrong
This is a retrospective study using existing data, not a real-world test. The AI may not work as well in different hospitals or populations, and it only screens for risk, not a diagnosis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 595 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients selected hospitals in the Netherlands and UK that have previously had chest x-rays and DXA scans

Ages

50 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥50 years at the time of chest X-ray 2. Availability of 1. Posteroanterior (PA) Chest X-ray and 2. DXA scan with a valid T-score measurement where both the DXA scan and Chest x-ray examinations were performed within 6 months (182 days) of each other and 3. Available X-ray and DXA scans performed on or after 01-Jan-2010. 3. Complete metadata (sex and age) available on PACS or hospital records. Exclusion Criteria: 1. Non-diagnostic Quality or Incomplete Imaging of: 1. DXA scan inadequacy: Missing T-score from a technically inadequate scan. 2. PA Chest X-ray technical inadequacy: Non-PA projection, significant motion artefacts, inadequate visualisation of thoracic structures, or missing DICOM metadata. 3. Image format incompatibility: Non-DICOM format or corrupted image files that would prevent AI analysis 4. PA Chest X-ray \> ±6 months from the date of the DXA scan. 2. Previous diagnosis or treatment of Osteoporosis prior to the DXA scan used in the Study. 1. diagnosis of osteoporosis (T-score ≤-2.5), or current/recent anti- osteoporotic medications, within 12 months prior to the DXA scan used in the study. 2. Current or recent anti-osteoporotic medications for 3 months (91 days) continuously prior to the Chest x-ray used in the Study. 3. Diagnosis of any metabolic bone disease prior to the DXA scan used in the study. 4. Diagnosis of metabolic bone disease other than Osteoporosis or Osteopenia, up to a maximum of 3 months (91 days) after the DXA scan. 5. Major Chest Wall or Spinal Deformities, including but not limited to: 1. Severe structural deformities: Thoracic scoliosis with Cobb angle \>40°, severe kyphosis, or chest wall deformities (pectus excavatum/carinatum) affecting \>30% of the thoracic cage. 2. Surgical hardware: Previous thoracic/spinal surgery with metallic implants obscuring anatomical landmarks required for AI analysis. 3. Pathological conditions: Extensive pulmonary consolidation, pleural effusion, lesions or masses obscuring \>30% of thoracic skeletal structures 6. Subject has opted out of confidential data being used for research purposes

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoporosis, osteopenia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Bone Diseases, Metabolic osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Barts Health NHS Trust

    RECRUITING

    London, E1 4DG, United Kingdom

  • Erasmus University Medical Center Rotterdam,

    NOT_YET_RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Mid and South Essex NHS Foundation Trust

    NOT_YET_RECRUITING

    Westcliff-on-Sea, Essex, SS0 0RY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.